Pharmaceutical industry – Page 40
-
Opinion
Drugs in a class of their own
New drug types need careful regulation to reward innovation while protecting patients
-
BusinessFemale sexual desire drug approved
Concerns raised over efficacy, side effects and use of advocacy campaigning to influence regulatory decisions
-
BusinessIndian pharma under increased regulatory scrutiny
Import bans and tightened rules pose a significant challenge for companies
-
BusinessPorous pills could be largest industrial 3D printing use
US grants first-of-a-kind approval for Aprecia’s epilepsy tablets exploiting porous structure
-
BusinessGreek crisis puts pressure on pharmaceuticals
Public spending cuts and capital restrictions on banks have exacerbated drug supply problems in Greece
-
BusinessNo one should be denied medication
Exclusive interview with Yusuf Hamied, chairman of Indian generic drugmaker Cipla
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
OpinionA precision instrument?
Chemists and biologists have different expectations when it comes to data, says Derek Lowe
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Biogen to develop gene therapies with AGTC
$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases
-
BusinessChemical firms seek better grasp of biomanufacturing
The search is on for better alternatives to the ‘broken’ way companies harness compound-making organisms
-
Business
US import ban imposed on Indian pharma firm
Concerns over manufacturing processes at Emcure facility prompts Food and Drug Administration to block drug shipments
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs